Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE NASDAQ:SIGA NASDAQ:TARS NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$36.59-4.5%$40.24$26.20▼$63.50$1.76B1.43809,292 shs856,298 shsSIGASiga Technologies$7.26+10.0%$6.56$4.95▼$12.83$471.51M0.94342,896 shs1.35 million shsTARSTarsus Pharmaceuticals$41.70+1.3%$41.36$22.44▼$57.28$1.73B0.79582,822 shs671,964 shsVCELVericel$36.29-1.4%$40.66$33.09▼$63.00$1.86B1.27648,880 shs569,583 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics-4.53%-2.70%-6.75%-3.22%-12.35%SIGASiga Technologies+10.00%+8.85%+7.88%+33.33%-15.04%TARSTarsus Pharmaceuticals+1.34%+4.25%+4.43%-11.54%+80.21%VCELVericel-1.44%-10.75%-7.92%-13.33%-22.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPGEApogee Therapeutics2.6648 of 5 stars3.50.00.00.04.04.20.0SIGASiga Technologies1.1786 of 5 stars0.02.00.00.00.00.83.1TARSTarsus Pharmaceuticals2.569 of 5 stars3.52.00.00.02.91.70.6VCELVericel2.2662 of 5 stars3.50.00.00.03.00.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 3.00Buy$99.00170.54% UpsideSIGASiga Technologies 0.00N/AN/AN/ATARSTarsus Pharmaceuticals 3.00Buy$66.6759.87% UpsideVCELVericel 3.00Buy$59.8664.94% UpsideCurrent Analyst Ratings BreakdownLatest SIGA, VCEL, APGE, and TARS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/1/2025VCELVericelCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$61.00 ➝ $58.007/7/2025APGEApogee TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/7/2025APGEApogee TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.007/7/2025APGEApogee TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$100.00 ➝ $115.007/2/2025APGEApogee TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$116.006/16/2025VCELVericelStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$67.006/2/2025TARSTarsus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$75.005/27/2025TARSTarsus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$72.005/22/2025VCELVericelStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.00(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$15.92 per shareN/ASIGASiga Technologies$138.72M3.74$0.92 per share7.89$3.02 per share2.40TARSTarsus Pharmaceuticals$182.95M9.58N/AN/A$5.87 per share7.10VCELVericel$237.22M7.72$0.31 per share117.83$6.08 per share5.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$182.15M-$3.60N/AN/AN/AN/A-28.35%-26.98%8/11/2025 (Estimated)SIGASiga Technologies$59.21M$0.676.425.81N/A45.73%40.97%35.87%N/ATARSTarsus Pharmaceuticals-$115.55M-$2.73N/AN/AN/A-44.91%-39.72%-25.74%N/AVCELVericel$10.36M$0.12302.4482.48N/A2.85%2.47%1.69%N/ALatest SIGA, VCEL, APGE, and TARS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025APGEApogee Therapeutics-$1.08N/AN/AN/AN/AN/A8/6/2025Q2 2025TARSTarsus Pharmaceuticals-$0.33-$0.48-$0.15-$0.48$95.81 million$102.66 million8/5/2025Q2 2025SIGASiga TechnologiesN/A$0.49N/A$0.49N/A$81.12 million7/31/2025Q2 2025VCELVericel-$0.04-$0.01+$0.03-$0.01$64.61 million$63.24 million5/12/2025Q1 2025APGEApogee Therapeutics-$1.19-$0.95+$0.24-$0.95N/AN/A5/8/2025Q1 2025SIGASiga TechnologiesN/A-$0.01N/A-$0.01N/A$7.04 million5/8/2025Q1 2025VCELVericel-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A15.8215.82SIGASiga TechnologiesN/A8.406.28TARSTarsus Pharmaceuticals0.215.575.54VCELVericelN/A4.974.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%SIGASiga Technologies55.40%TARSTarsus Pharmaceuticals90.01%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics42.77%SIGASiga Technologies1.95%TARSTarsus Pharmaceuticals8.97%VCELVericel5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9146.05 million26.35 millionOptionableSIGASiga Technologies4071.44 million70.05 millionOptionableTARSTarsus Pharmaceuticals5042.01 million38.25 millionOptionableVCELVericel30050.46 million47.84 millionOptionableSIGA, VCEL, APGE, and TARS HeadlinesRecent News About These CompaniesVericel Q2 Revenue Jumps 20%August 5 at 4:08 PM | fool.comVericel Corporation (NASDAQ:VCEL) Short Interest Up 308.4% in JulyAugust 5 at 3:35 AM | americanbankingnews.comVericel FY2025 EPS Forecast Decreased by Leerink PartnrsAugust 5 at 2:15 AM | americanbankingnews.comVericel Corporation (NASDAQ:VCEL) Shares Purchased by Geneva Capital Management LLCAugust 4 at 3:19 AM | marketbeat.comCanaccord Genuity Group Cuts Vericel (NASDAQ:VCEL) Price Target to $58.00August 4 at 2:41 AM | americanbankingnews.comFY2025 EPS Estimates for Vericel Decreased by AnalystAugust 4 at 2:00 AM | marketbeat.comVericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.03 EPSAugust 3, 2025 | marketbeat.comVericel Corporation (NASDAQ:VCEL) Short Interest UpdateAugust 3, 2025 | marketbeat.comVericel Corporation (NASDAQ:VCEL) Shares Sold by Baker Avenue Asset Management LPAugust 3, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Price Target Cut to $58.00 by Analysts at Canaccord Genuity GroupAugust 2, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Hits New 52-Week Low - Here's What HappenedAugust 2, 2025 | marketbeat.comVericel Corporation (NASDAQ:VCEL) Q2 2025 Earnings Call TranscriptAugust 2, 2025 | msn.comVericel Corporation Reports Strong Q2 2025 EarningsAugust 1, 2025 | tipranks.comVericel (NASDAQ:VCEL) Shares Gap Down - Here's What HappenedAugust 1, 2025 | marketbeat.comEarnings To Watch: Vericel Corp (VCEL) Reports Q2 2025 ResultAugust 1, 2025 | finance.yahoo.comVericel Corporation (VCEL) Q2 2025 Earnings Call TranscriptAugust 1, 2025 | seekingalpha.comVericel Corporation Reports Strong Q2 2025 ResultsJuly 31, 2025 | tipranks.comVericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue EstimatesJuly 31, 2025 | zacks.comVericel Reports Second Quarter 2025 Financial ResultsJuly 31, 2025 | globenewswire.comVericel Corporation (NASDAQ:VCEL) Shares Bought by Federated Hermes Inc.July 31, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Acquires New Holdings in Vericel Corporation (NASDAQ:VCEL)July 31, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSIGA, VCEL, APGE, and TARS Company DescriptionsApogee Therapeutics NASDAQ:APGE$36.59 -1.74 (-4.53%) Closing price 08/6/2025 03:59 PM EasternExtended Trading$40.00 +3.41 (+9.31%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Siga Technologies NASDAQ:SIGA$7.26 +0.66 (+10.00%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$7.08 -0.18 (-2.53%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.Tarsus Pharmaceuticals NASDAQ:TARS$41.70 +0.55 (+1.34%) Closing price 08/6/2025 03:59 PM EasternExtended Trading$42.75 +1.05 (+2.52%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.Vericel NASDAQ:VCEL$36.29 -0.53 (-1.44%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$38.83 +2.54 (+7.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Joby Deal Gives Blade New Direction, But Stock Lacks Lift How DigitalOcean's Focus Is Fueling Explosive Growth Disney’s Iger-Led Turnaround Gains Traction Can Celsius Stock Keep Its Momentum Going Any Longer? AMD’s Results Sparked a Sell-Off—But That’s Your Buy Signal Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 Lifeline Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNX RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
